Abstract Search

ey0021.10-1 | Clinical Trials – New Treatments | ESPEYB21

10.1. Baricitinib and beta-cell function in patients with new-onset type 1 diabetes

M Waibel , JM Wentworth , M So , JJ Couper , FJ Cameron , RJ MacIsaac , al. et

Brief Summary: This phase 2, double-blind, placebo-controlled trial, randomized 91 people (10-30 years-old) diagnosed with type 1 diabetes (T1D) within the previous 100 days to receive either oral baricitinib (n=60) or placebo (n=31) for 48 weeks. Baricitinib was safe and preserved the capacity of β-cells to secrete insulin.Baricitinib is a Janus kinase (JAK) inhibitor blocking cytokine signalling and is already an effective disease-modifying treatm...

0 shares

ey0019.10-2 | Reviews | ESPEYB19

10.2. Screening for type 1 diabetes in the general population: a status report and perspective

EK Sims , REJ Besser , C Dayan , Rasmussen C Geno , C Greenbaum , KJ Griffin , W Hagopian , M Knip , AE Long , F Martin , C Mathieu , M Rewers , AK Steck , JM Wentworth , SS Rich , O Kordonouri , AG Ziegler , KC Herold

NIDDK Type 1 Diabetes TrialNet Study Group.Diabetes. 2022 Apr 1;71(4):610-623. https://pubmed.ncbi.nlm.nih.gov/35316839/Brief Summary: This is a comprehensive review on general population screening, a current hot topic in the field of type 1 diabetes (T1D). The authors provide a critical overview of the rationale for population screening, arguments for and against it, current efforts to gui...

0 shares

ESPE Yearbook of Paediatric Endocrinology

10.1. Baricitinib and beta-cell function in patients with new-onset type 1 diabetes

10.2. Screening for type 1 diabetes in the general population: a status report and perspective

BiosciAbstracts